Would you consider maintenance immunotherapy following chemoradiation for a patient with an isolated mediastinal recurrence of NSCLC?

For patients with loco-regional recurrent NSCLC treated with definitive chemoradiation, I would offer durvalumab consolidation since I would consider this on-label treatment (i.e inoperable stage III NSCLC - even TxN2 - treated with definitive chemoradiation). Other nuances of N2 NSCLC in the era of PACIFIC have come up in a few other questions here as well and are worth a look: here and here. The issue of offering durva to patients based on PD-L1 status has also come up previously as well.